A single arm, Phase III trial of BC 819 in patients with bladder cancer who did not respond to initial treatment with BCG.

Trial Profile

A single arm, Phase III trial of BC 819 in patients with bladder cancer who did not respond to initial treatment with BCG.

Planning
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs BC 819 (Primary)
  • Indications Bladder cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BCG Failure
  • Sponsors BioCancell Therapeutics
  • Most Recent Events

    • 14 Aug 2017 This trial will be performed under a Special Protocol Assessment provision of the US FDA, as reported in a BioCancell Therapeutics media release
    • 14 Aug 2017 According to a BioCancell Therapeutics media release, this trial is expected to be initiated in 2017.
    • 10 Sep 2015 Planned initiation date changed from 1 Dec 2015 to 1 Jan 2016 according to a BioCancell Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top